The present invention is generally directed to deuterated agonists and their methods of use. It is more specifically directed to deuterated alpha-7 nicotinic receptor agonists and their methods of use. In one aspect, the present invention involves compounds of the structure 1-34 as shown in FIGS. 1-4. In another aspect, the present invention involves the treatment of a disorder with a compound of the structure 1-34 as shown in FIGS. 1-4.